演題詳細

ポスター / Poster

ポスター 9 (Poster 9) :CML:臨床1 (CML:Clinical Research 1)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
田中 英夫 (Hideo Tanaka):1
1:広島市立安佐市民病院 血液内科
 
前へ戻る

Long-term outcome of imatinib therapy for patients with chronic myeloid leukemia in single institute

演題番号 : PS-1-63

瀧本 円 (Madoka Takimoto):1、小川 考平 (Kohei Ogawa):1、横井 聡 (Satoshi Yokoi):1、佐野 文明 (Fumiaki Sano):1、三浦 偉久男 (Ikuo Miura):2

1:Int. Med, Hematology, Yokohama City Seibu Hospital, St. Marianna Univ、2:Department of Internal Medicine, Division of Hematology,St. Marianna University School of Medicine

 

BACKGROUND: Tyrosine kinase inhibitor (TKI) therapy with imatinib (IM) is very effective in chronic-phase chronic myeloid leukemia (CML). Recently, second TKI such as dasatinib and nilotinib can be used as first line therapy in Japan. However, many patients were continued IM therapy for long time. In this study, we assessed the long-term effect and toxicity of IM therapy. METHODS: From 2001 to 2012, forty-four patients with chronic-phase CML were received IM therapy in our hospital. Efficacy was assessed by complete hematological response, complete cytogenetic response (CCyR) and major molecular response (MMR) or complete molecular response (CMR) using Amp-CML. Toxicity was graded according to CTCAEv4.0. RESULTS: Thirty-nine patients with median age of 58 years (range 21-88) were evaluable. Twenty-two patients were men and 17 were women. Six patients were previously treated with interferon &alpha. The median follow-up time was 69 months (range 2-115). Median dosage of IM was 400mg and 12 patients reduced the dosage because of toxicity. Eight patients were switched to second TKI because of unsatisfactory efficacy or adverse events. Estimated cumulative rate of CCyR, MMR and CMR were 86%, 72%, 50%, respectively. The estimated over all survival rates at 8 year was 95%. Most common grade 3 or 4 adverse events were neutropenia, thrombocytopenia and peripheral edema. CONCLUSION: Long-term imatinib therapy was effective and tolerable for Japanese patients with CML.

前へ戻る